STOCK TITAN

Azenta Inc - AZTA STOCK NEWS

Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.

Azenta Inc. (Nasdaq: AZTA) is a globally recognized provider of life sciences solutions, dedicated to accelerating impactful scientific breakthroughs and therapies. Headquartered in Burlington, Massachusetts, Azenta operates across North America, Europe, and Asia, delivering an extensive portfolio of products and services designed to meet the complex needs of the pharmaceutical, biotech, academic, and healthcare sectors. The company's offerings are structured into two primary segments: Life Sciences Products and Life Sciences Services, with the latter driving a significant portion of its revenue.

Core Business Areas

Azenta specializes in cold-chain sample management solutions and genomic and multiomics services. Its cold-chain solutions ensure the integrity of biological samples throughout the storage and transportation process, a critical requirement for drug development and clinical research. Complementing this, its genomic services, including next-generation sequencing (NGS) and long-read Whole Genome Sequencing (WGS), enable precise genetic analysis, facilitating advanced research in areas such as rare diseases, personalized medicine, and cell therapies.

Innovative Technologies and Solutions

Azenta is at the forefront of technological innovation in life sciences. Its automated sample storage systems, such as the BioArc™ Ultra, offer high-density, eco-friendly storage solutions that support large-scale research initiatives like the UK's Our Future Health program. The company's long-read WGS test, performed using PacBio's Revio sequencer, represents a breakthrough in clinical genomics, enabling the detection of complex genetic variants previously inaccessible through traditional methods. These innovations underscore Azenta's commitment to enhancing research efficiency and accuracy while advancing sustainability in science.

Market Position and Competitive Landscape

Operating in a highly competitive industry, Azenta differentiates itself through its comprehensive suite of services, global reach, and focus on cutting-edge technologies. Its partnerships with leading organizations, such as the Crohn's & Colitis Foundation and the FinnGen project, highlight its role as a trusted collaborator in groundbreaking research. Additionally, its emphasis on sustainability and operational efficiency positions it as a forward-thinking leader in the life sciences sector.

Commitment to Sustainability and Operational Excellence

Azenta integrates eco-friendly practices into its operations, as exemplified by its BioArc Ultra system, which reduces electricity usage and supports carbon emission reduction goals. The company also focuses on streamlining workflows and enhancing profitability through disciplined execution of its transformation initiatives, ensuring long-term scalability and efficiency.

Global Impact and Future Outlook

Through its advanced solutions and strategic partnerships, Azenta plays a pivotal role in enabling faster development of therapies and diagnostics. Its contributions to large-scale research initiatives and its focus on personalized medicine underscore its significance in addressing global healthcare challenges. With a strong foundation and a clear growth strategy, Azenta is well-positioned to continue driving innovation and delivering value to its stakeholders.

Key Offerings

  • Cold-chain sample management solutions
  • Multiomics services, including genomics and proteomics
  • Automated sample storage systems
  • Clinical-grade long-read Whole Genome Sequencing
  • Advanced bioinformatics and data analysis

Azenta's dedication to enabling impactful scientific breakthroughs, combined with its innovative technologies and strategic partnerships, solidifies its position as a leader in the life sciences industry.

Rhea-AI Summary
Azenta, Inc. (AZTA) to participate in 1x1 meetings at Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences
-
Rhea-AI Summary
Azenta, Inc. (Nasdaq: AZTA) reported Q4'23 revenue growth of 25% year over year and 2% on an organic basis. Fiscal year 2023 revenue grew by 20%, with organic growth down 1%. Positive free cash flow was generated for the second consecutive quarter. Fiscal 2024 expects 5-8% organic revenue growth and an additional $500 million in share repurchases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.89%
Tags
-
Rhea-AI Summary
Azenta, Inc. (Nasdaq: AZTA) has nominated Didier Hirsch and Martin Madaus for election to the Board of Directors at the 2024 Annual Meeting of Stockholders. The company also reported strong 2023 fourth quarter and full year fiscal 2023 earnings results, with a commitment to an additional $500 million in share repurchases in Fiscal 2024. This follows a significant strategic transformation since 2021, including the sale of its semiconductor automation business in 2022 and the implementation of cost reduction initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.89%
Tags
none
Rhea-AI Summary
Azenta, Inc. (Nasdaq: AZTA) announced a Memorandum of Understanding (MOU) between B Medical Systems S.à r.l and The Ministry of Public Health, Hygiene and Prevention of the Democratic Republic of the Congo for a €100 million National Vaccination Service project. This project includes the delivery of a complete solution for vaccine storage and transport, Toyota vehicles customized with cold chain solutions, and other equipment, with over 50% of the project value expected to be recognized as B Medical revenue for Azenta.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.89%
Tags
none
-
Rhea-AI Summary
Azenta, Inc. (Nasdaq: AZTA) to Participate in Stephens Annual Investment Conference in Nashville, Tennessee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
-
Rhea-AI Summary
Azenta, Inc. (Nasdaq: AZTA) to announce fiscal Q4 and full year 2023 earnings on November 13, 2023. Conference call and webcast to discuss financial results. Access live webcast at https://investors.azenta.com/events. Replay available on November 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
Rhea-AI Summary
Azenta, Inc. to host GENEWIZ Week featuring virtual workshops and grant program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences
-
News
Rhea-AI Summary
Azenta announces new CFO and reaffirms guidance for Q4 fiscal 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
Rhea-AI Summary
Azenta, Inc. to present at Morgan Stanley Global Healthcare Conference on September 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
conferences
Rhea-AI Summary
Azenta, Inc. to present at Baird 2023 Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
conferences

FAQ

What is the current stock price of Azenta (AZTA)?

The current stock price of Azenta (AZTA) is $43.62 as of February 28, 2025.

What is the market cap of Azenta (AZTA)?

The market cap of Azenta (AZTA) is approximately 2.1B.

What does Azenta Inc. specialize in?

Azenta specializes in cold-chain sample management and genomic services, supporting drug development, clinical research, and advanced cell therapies.

How does Azenta generate revenue?

Azenta generates revenue through its Life Sciences Products and Life Sciences Services segments, with services contributing significantly to its income.

What industries does Azenta serve?

Azenta serves pharmaceutical, biotech, academic, and healthcare institutions globally, providing solutions for drug development, clinical research, and personalized medicine.

What are Azenta's key innovations?

Key innovations include automated sample storage systems like the BioArc Ultra and clinical-grade long-read Whole Genome Sequencing for advanced genomic analysis.

How does Azenta support sustainability in science?

Azenta integrates eco-friendly practices, such as energy-efficient sample storage systems, to reduce carbon emissions and advance sustainability in scientific research.

What partnerships highlight Azenta's role in research?

Azenta collaborates with organizations like FinnGen and the Crohn's & Colitis Foundation, supporting large-scale research initiatives and advancing healthcare innovation.

What is Azenta's competitive advantage?

Azenta's competitive advantage lies in its comprehensive solutions, global reach, advanced technologies, and focus on personalized medicine and sustainability.

Where is Azenta headquartered?

Azenta is headquartered in Burlington, Massachusetts, with operations across North America, Europe, and Asia.

What role does Azenta play in personalized medicine?

Azenta enables personalized medicine through advanced genomic and proteomic services, helping researchers uncover disease mechanisms and develop targeted therapies.

How does Azenta support large-scale research projects?

Azenta provides automated sample storage and genomic services to support initiatives like the UK's Our Future Health program and the FinnGen project.
Azenta Inc

Nasdaq:AZTA

AZTA Rankings

AZTA Stock Data

2.10B
44.86M
1.66%
110.42%
9.26%
Medical Instruments & Supplies
Special Industry Machinery, Nec
Link
United States
BURLINGTON